

Key Trends for Active Employees and Early Retirees Based on Paid Claims Through October 2024 Rolling Year

November 2024



Key Observations


For paid claims from November 2023 – October 2024:

- Medical and prescription drug allowed amount increased by 11.3% percent (Slide 3) driven by a 21.2% increase in allowed amount for prescription drugs (Slide 4).
- Total membership increased by 2.4% over the prior rolling year period while employee enrollment increased by 3.3 percent (Slide 5).
- Plan payments on a PMPY basis increased by 11.9% for outpatient radiology and 14.2% for mental health and substance abuse services (Slide 6).
- Admissions per 1,000 decreased by 4.9% (Slide 9), largely driven by decreases in surgical admissions (-10%) and maternity (-6.4%).
- While the allowed amount for admissions increased marginally overall by 1.5% (Slide 10), the allowed amount per admission and the allowed amount per day stay increased by 6.5% and 7.6%, respectively (Slide 11).
- The allowed amount PMPY for specialty drugs under the medical benefit increased by 15.4% and utilization for specialty drugs under the medical benefit increased by 11.3 percent. The cost and utilization of outpatient substance abuse services increased by 17.4% on an allowed amount PMPY basis and 11.0% on a total patients basis (Slide 13).
- Payments on a PMPY basis increased for PET scans (17.5%), nuclear medicine (41.6%), and therapeutic radiology (26.3%) contributing to an overall 11.9% increase in plan payments for outpatient radiology (Slide 16). See appendix for further detail for PET scans, nuclear medicine and therapeutic radiology by place of service.
- For lab services, plan payments on a PMPY basis continued to decrease. As noted in previous months, the decrease is largely attributable to a decrease in COVID-19 testing (slide 17).
- The total allowed amount per patient increased by 26.1% for breast cancer (Slide 24).

Overall Trend


Annual Trend

| | Nov 2022 – | Nov 2023 – | |
|--------------------------|---------------|-----------------|----------|
| | Oct 2023 | Oct 2024 | % Change |
| Allowed Amount | \$935,173,171 | \$1,040,684,864 | 11.3% |
| Coordination of Benefits | \$21,649,877 | \$26,260,217 | 21.3% |
| Out of Pocket | \$47,502,907 | \$54,315,933 | 14.3% |
| Net Payment | \$866,020,386 | \$960,108,714 | 10.9% |
| Members Avg Med or Rx | 100,401 | 102,799 | 2.4% |
| Allow Amt PMPY | \$9,314 | \$10,123 | 8.7% |
| Allow Amt PEPY | \$20,455 | \$22,030 | 7.7% |
| Net Pay PMPY | \$8,626 | \$9,340 | 8.3% |
| Net Pay PEPY | \$18,943 | \$20,325 | 7.3% |



¹Increase in Coordination of Benefits is largely due to the addition of PrudentRx Claims. Coordination of Benefits for PrudentRx consists of a "residual copay required by the manufacturer or the remaining drug cost after the program benefits are exhausted or unavailable. This amount is billed back to the plan" (CVS Report Definitions, State of DE State Employee Benefits Comm Savings Report). This does not include any savings, which are not included in this report and not included in the overall Allowed Amount.

Overall PMPY Trend




Allowed Amount PMPY Trend

| | Nov 2022 – | Nov 2023 – | |
|-------------------|------------|------------|----------|
| | Oct 2023 | Oct 2024 | % Change |
| IP Medical | \$1,881 | \$1,921 | 2.1% |
| OP Medical | \$5,184 | \$5,484 | 5.8% |
| Prescription Drug | \$2,184 | \$2,647 | 21.2% |

Overall Eligibility Trend

Annual Eligibility Trend


| | Nov 2022 – | Nov 2023 – | |
|---------------------|------------|------------|----------|
| | Oct 2023 | Oct 2024 | % Change |
| Members Avg | 100,373 | 102,764 | 2.4% |
| Employees | 45,718 | 47,239 | 3.3% |
| Spouses | 15,384 | 15,393 | 0.1% |
| Children/Dependents | 39,270 | 40,132 | 2.2% |
| Family Size Avg | 2.2 | 2.2 | -0.9% |
| Member Age Avg | 34.4 | 34.3 | -0.1% |
| Employees | 47.0 | 46.9 | -0.3% |
| Spouses | 49.9 | 49.9 | 0.1% |
| Children/Dependents | 13.5 | 13.6 | 0.3% |




Overall Trend by Type of Service

| | Allowed | Amt PMPY Med and | Rx | Net Pay P | MPY Med and Rx | |
|---------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|
| | Nov 2022 – Oct 2023 | Nov 2023 – Oct 2024 | % Change | Nov 2022 – Oct 2023 | Nov 2023 – Oct 2024 | % Change |
| IP Facility | \$1,612 | \$1,638 | 1.7% | \$1,527 | \$1,562 | 2.3% |
| IP Professional | \$185 | \$183 | -0.8% | \$177 | \$175 | -1.0% |
| OP Major Procedures | \$1,374 | \$1,396 | 1.6% | \$1,303 | \$1,325 | 1.6% |
| OP Radiology | \$429 | \$480 | 12.0% | \$403 | \$451 | 11.9% |
| OP Office Visits | \$641 | \$690 | 7.7% | \$548 | \$593 | 8.0% |
| OP Lab | \$266 | \$236 | -11.4% | \$233 | \$206 | -11.5% |
| OP Emergency Room | \$649 | \$682 | 5.2% | \$589 | \$617 | 4.9% |
| OP Other | \$420 | \$440 | 4.8% | \$430 | \$458 | 6.6% |
| MHSA | \$395 | \$456 | 15.3% | \$364 | \$416 | 14.2% |
| Prescription Drugs | \$2,184 | \$2 <i>,</i> 647 | 21.2% | \$2,003 | \$2,372 | 18.4% |

Allowed Amount PMPM Quarterly Trend






Cost and Use by Type of Service

| | Patients as a % of | Costs as a % of |
|-------------------------|--------------------|----------------------|
| | Total Members | Total Allowed Amount |
| IP Facility | 3.9% | 18.5% |
| IP Professional | 5.1% | 2.1% |
| OP Major Procedures | 16.2% | 15.8% |
| OP Radiology | 37.1% | 5.4% |
| OP Office Visits | 83.8% | 7.8% |
| OP Lab | 60.9% | 2.7% |
| OP Emergency Room | 15.4% | 7.7% |
| OP Other | 78.5% | 5.0% |
| MHSA | 22.3% | 5.2% |
| Prescription Drugs | 75.7% | 29.9% |




Acute Inpatient Admission Detail

| | | NI 2022 | |
|---|------------|------------|----------|
| | Nov 2022 – | Nov 2023 – | |
| | Oct 2023 | Oct 2024 | % Change |
| Medical | 18.4 | 18.0 | -2.3% |
| မ္မိ Maternity | 21.4 | 20.2 | -5.4% |
| Maternity Surgical MHSA | 10.4 | 9.1 | -12.4% |
| ^튣 MHSA | 6.1 | 6.1 | -1.4% |
| Total | 56.4 | 53.4 | -5.2% |
| [≽] Medical | \$614 | \$658 | 7.1% |
| ਤੂ Maternity | \$386 | \$410 | 6.1% |
| 쇼 Medical 법 Maternity 딸 Surgical 행 MHSA 당 Total | \$756 | \$700 | -7.3% |
| MHSA | \$87 | \$91 | 5.6% |
| Total | \$1,843 | \$1,860 | 0.9% |
| Medical | \$597 | \$638 | 6.8% |
| Maternity | \$362 | \$386 | 6.6% |
| A Maternity a Surgical | \$723 | \$676 | -6.4% |
| MHSA | \$83 | \$88 | 6.3% |
| Total | \$1,764 | \$1,788 | 1.3% |
| | | | |




Admission PMPY Allowed Amount Trend*

| | Nov 2022 – Oct 2023 | Nov 2023 – Oct 2024 | % Change |
|------------------|------------------------|------------------------|----------|
| Allowed Amt PMPY | | | |
| Facility | \$1,595 | \$1,619 | 1.5% |
| Professional | \$175 | \$174 | -0.7% |
| Total | \$1,770 | \$1,793 | 1.3% |
| Net Pay PMPY | | | |
| Facility | \$1,513 | \$1,544 | 2.1% |
| Professional | \$167 | \$166 | -0.9% |
| Total | \$1,680 | \$1,710 | 1.8% |



Acute Admission Detail*


| | Nov 2022 – | Nov 2023 – | |
|-------------------|------------|-------------------|----------|
| | Oct 2023 | Oct 2024 | % Change |
| Length of Stay | | | |
| Medical | 5.5 | 5.5 | 0.4% |
| Surgical | 6.5 | 6.2 | -3.9% |
| Maternity | 3.0 | 3.0 | 1.5% |
| MHSA | 10.3 | 10.0 | -3.7% |
| Total | 5.2 | 5.2 | -1.0% |
| Allowed Amt/Admit | | | |
| Medical | \$33,384 | \$36 <i>,</i> 620 | 9.7% |
| Surgical | \$72,410 | \$76,591 | 5.8% |
| Maternity | \$18,059 | \$20,247 | 12.1% |
| MHSA | \$14,096 | \$15,095 | 7.1% |
| Total | \$32,692 | \$34,815 | 6.5% |
| Allowed Amt/Day | | | |
| Medical | \$6,101 | \$6,668 | 9.3% |
| Surgical | \$11,204 | \$12 <i>,</i> 332 | 10.1% |
| Maternity | \$6,044 | \$6 <i>,</i> 678 | 10.5% |
| MHSA | \$1,362 | \$1,514 | 11.2% |
| Total | \$6,234 | \$6 <i>,</i> 708 | 7.6% |



Acute Inpatient Admission Detail: Current Year Surgical Admits*

\$0

\$2,000,000



\$4.000.000

\$6.000.000

\$8.000.000

\$10,000,000

\$12.000.000

Outpatient Medical Detail

| | Allowe | d Amt PMPY Med | | Pat | ients | |
|----------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|
| | Nov 2022 – Oct 2023 | Nov 2023 – Oct 2024 | % Change | Nov 2022 – Oct 2023 | Nov 2023 – Oct 2024 | % Change |
| Major Procedures | \$1,374 | \$1,396 | 1.6% | 17,490 | 18,481 | 5.7% |
| Specialty Drugs (Medical) | \$628 | \$725 | 15.4% | 3,516 | 3,914 | 11.3% |
| Professional Office Visits | \$641 | \$690 | 7.7% | 93,668 | 95,416 | 1.9% |
| Emergency Rooms | \$649 | \$682 | 5.2% | 18,292 | 17,497 | -4.3% |
| Radiology | \$429 | \$480 | 12.0% | 41,632 | 42,205 | 1.4% |
| Other Outpatient Services | \$420 | \$440 | 4.8% | 82,119 | 89,414 | 8.9% |
| Laboratory | \$266 | \$236 | -11.4% | 69,214 | 69,412 | 0.3% |
| Mental Health | \$281 | \$324 | 15.4% | 23,696 | 24,748 | 4.4% |
| Substance Abuse | \$29 | \$34 | 17.4% | 1,004 | 1,114 | 11.0% |
| PT, OT, Speech Therapy | \$149 | \$160 | 7.0% | 15,710 | 16,147 | 2.8% |
| Injections and Medications | \$79 | \$73 | -7.8% | 12,666 | 12,662 | 0.0% |
| Supplies and Devices | \$95 | \$100 | 5.7% | 14,353 | 15,248 | 6.2% |
| Dialysis | \$67 | \$67 | -0.1% | 102 | 94 | -7.8% |
| Durable Medical Equipment | \$39 | \$36 | -6.7% | 4,625 | 4,863 | 5.1% |

Outpatient Medical Detail

| | Utilization (Services per 1000) | | | Price (Allowed Ar | mount per Service) | |
|----------------------------|---------------------------------|------------------------|----------|------------------------|------------------------|----------|
| | Nov 2022 – Oct 2023 | Nov 2023 – Oct 2024 | % Change | Nov 2022 – Oct 2023 | Nov 2023 – Oct 2024 | % Change |
| Major Procedures | 1,957.2 | 1,879.5 | -4.0% | \$702 | \$743 | 5.8% |
| Specialty Drugs (Medical) | 295.5 | 295.6 | 0.0% | \$2,126 | \$2,453 | 15.4% |
| Professional Office Visits | 5,715.0 | 5,797.3 | 1.4% | \$112 | \$119 | 6.1% |
| Emergency Rooms | 2,159.0 | 2,066.8 | -4.3% | \$300 | \$330 | 9.9% |
| Radiology | 1,769.3 | 1,676.9 | -5.2% | \$242 | \$286 | 18.2% |
| Other Outpatient Services | 3,559.4 | 3,890.5 | 9.3% | \$118 | \$113 | -4.2% |
| Laboratory | 7,270.4 | 7,240.2 | -0.4% | \$37 | \$33 | -11.1% |
| Mental Health | 2,697.2 | 2,893.8 | 7.3% | \$104 | \$112 | 7.5% |
| Substance Abuse | 213.6 | 247.7 | 16.0% | \$136 | \$138 | 1.3% |
| PT, OT, Speech Therapy | 4,324.3 | 4,503.7 | 4.1% | \$35 | \$35 | 2.8% |
| Injections and Medications | 808.3 | 794.8 | -1.7% | \$98 | \$92 | -6.3% |
| Supplies and Devices | 1,166.8 | 1,276.3 | 9.4% | \$81 | \$79 | -3.4% |
| Dialysis | 105.2 | 109.9 | 4.5% | \$635 | \$607 | -4.4% |
| Durable Medical Equipment | 215.6 | 213.4 | -1.0% | \$179 | \$169 | -5.8% |

Outpatient Medical Detail: Professional Office Visits


| | | % Visits | | % | Allowed Amt | | Allow | ed Amount/\ | /isit | , | Visits per 100 | 00 |
|-----------------------|------------|--------------|--------|------------|-------------|--------|------------|--------------|--------|------------|----------------|----------|
| | Nov 2022 - | - Nov 2023 - | | Nov 2022 - | Nov 2023 - | | Nov 2022 · | - Nov 2023 - | % | Nov 2022 - | Nov 2023 - | |
| | Oct 2023 | Oct 2024 | Change | Oct 2023 | Oct 2024 | Change | Oct 2023 | Oct 2024 | Change | Oct 2023 | Oct 2024 | % Change |
| Specialist Visits | 35.7% | 6 34.9% | -0.8% | 34.8% | 6 34.1% | -0.7% | \$12 | 8 \$137 | 6.7% | 1,50 | 3 1,48 | 6 -1.1% |
| Non-Specialist Visits | 64.3% | 65.1% | 0.8% | 65.2% | 65.9% | 0.7% | \$13 | 3 \$141 | L 6.2% | 2,71 | 1 2,77 | 8 2.5% |
| Total | 100.0% | % 100.0% | ,) | 100.0% | 6 100.0% | • | \$13 | 1 \$140 | 6.4% | 4,21 | 3 4,26 | 3 1.2% |




| | Visits | Allowed Amount |
|-------------------------------|----------|----------------|
| | per 1000 | Per Visit |
| Dermatology | 192 | \$99 |
| Orthopaedic Surgery | 197 | \$129 |
| Cardiovascular Dis/Cardiology | 115 | \$139 |
| Podiatry | 109 | \$94 |
| Emergency Medicine | 76 | \$158 |
| Chiropractor/DCM | 60 | \$84 |
| Ophthalmology | 56 | \$125 |
| Urology | 49 | \$128 |
| Otolaryngology | 54 | \$164 |
| Pain Mgmt/Pain Medicine | 51 | \$116 |
| Surgeon (NEC) | 36 | \$147 |
| Neurology | 41 | \$178 |
| Endocrinology & Metabolism | 38 | \$152 |
| Allergy & Immunology | 43 | \$161 |
| Oncology | 41 | \$167 |
| Тор 15 | 1,153 | \$128 |
| All Other Specialists | 337 | \$164 |
| Total All Specialists | 1,486 | \$137 |

Outpatient Medical Detail: Radiology


| | Services per 1000 | | 00 | Allowed Amount per Service | | | Allowed Amount PMPY | | | Net Pay PMPY | | |
|------------------|-------------------|------------|----------|----------------------------|------------|----------|---------------------|------------|----------|--------------|------------|----------|
| Outpatient | | | | | | | | | | | | |
| Radiology | Nov 2022 - | Nov 2023 - | | Nov 2022 - | Nov 2023 - | | Nov 2022 - | Nov 2023 - | | Nov 2022 - | Nov 2023 - | |
| Services | Oct 2023 | Oct 2024 | % Change | Oct 2023 | Oct 2024 | % Change | Oct 2023 | Oct 2024 | % Change | Oct 2023 | Oct 2024 | % Change |
| CAT Scans | 94.8 | 91.9 | -3.0% | \$434 | \$467 | 7.5% | \$41 | \$43 | 4.3% | \$37 | \$38 | 2.3% |
| MRIs | 118.4 | 121.0 | 2.2% | \$564 | \$590 | 4.7% | \$67 | \$71 | 7.1% | \$62 | \$66 | 6.9% |
| Mammograms | 445.5 | 411.5 | -7.6% | \$120 | \$130 | 8.5% | \$53 | \$53 | 0.3% | \$52 | \$52 | 0.1% |
| PET Scans | 7.0 | 8.3 | 18.3% | \$2,814 | \$2,833 | 0.7% | \$20 | \$23 | 19.1% | \$19 | \$22 | 17.5% |
| Nuclear Medicine | 31.1 | 29.3 | -5.7% | \$744 | \$1,132 | 52.3% | \$23 | \$33 | 43.5% | \$22 | \$31 | 41.6% |
| Therapeutic | 98.9 | 115.6 | 16.9% | \$1,113 | \$1,205 | 8.3% | \$110 | \$139 | 26.6% | \$109 | \$137 | 26.3% |
| Ultrasounds | 418.7 | 383.9 | -8.3% | \$171 | \$189 | 10.4% | \$72 | \$73 | 1.2% | \$65 | \$66 | 1.2% |
| X-Rays | 521.9 | 483.3 | -7.4% | \$75 | \$82 | 9.8% | \$39 | \$40 | 1.7% | \$33 | \$34 | 2.4% |
| Other | 33.0 | 32.0 | -3.1% | \$116 | \$123 | 6.8% | \$4 | \$4 | 3.5% | \$4 | \$4 | 4.2% |
| Total | 1769.3 | 1676.9 | -5.2% | \$242 | \$286 | 18.2% | \$429 | \$480 | 12.0% | \$403 | \$451 | 11.9% |





Outpatient Medical Detail: Laboratory


| | Services per 1000 | | | Allowed Amount per Service | | | Allowed Amount PMPY | | | Net Pay PMPY | | |
|-----------------|-------------------|------------|----------|----------------------------|------------|----------|---------------------|------------|----------|--------------|------------|----------|
| Outpatient Lab | Nov 2022 - | Nov 2023 - | | Nov 2022 - | Nov 2023 - | | Nov 2022 - | Nov 2023 - | | Nov 2022 - | Nov 2023 - | |
| Services | Oct 2023 | Oct 2024 | % Change | Oct 2023 | Oct 2024 | % Change | Oct 2023 | Oct 2024 | % Change | Oct 2023 | Oct 2024 | % Change |
| Chemistry Tests | 3831.6 | 4026.5 | 5.1% | \$21 | \$21 | -2.2% | \$81 | \$83 | 2.8% | \$63 | \$67 | 5.7% |
| Hematology | 583.6 | 599.2 | 2.7% | \$18 | \$14 | -19.4% | \$10 | \$8 | -17.2% | \$7 | \$7 | 6.6% |
| Immunology | 606.0 | 549.3 | -9.4% | \$27 | \$28 | 5.6% | \$16 | \$16 | -4.3% | \$15 | \$14 | -5.9% |
| Microbiology | 1282.0 | 1127.1 | -12.1% | \$51 | \$42 | -17.9% | \$66 | \$48 | -27.8% | \$61 | \$42 | -30.3% |
| Pathology | 455.1 | 423.6 | -6.9% | \$142 | \$131 | -7.9% | \$65 | \$55 | -14.3% | \$60 | \$51 | -14.6% |
| Urinalysis | 321.4 | 321.8 | 0.1% | \$5 | \$5 | 4.6% | \$2 | \$2 | 4.7% | \$1 | \$2 | 5.5% |
| Other | 190.8 | 192.7 | 1.0% | \$141 | \$125 | -11.2% | \$27 | \$24 | -10.3% | \$25 | \$23 | -11.0% |
| Total | 7270.4 | 7240.2 | -0.4% | \$37 | \$33 | -11.1% | \$266 | \$236 | -11.4% | \$233 | \$206 | -11.5% |



Prescription Drug Detail*

Annual Trend

| Nov 2022 - Oct 2023 \$2,184 \$2,003 \$112 836.9 \$4.66 | Oct 2024 \$2,647 \$2,372 \$134 | 21.2% 18.4% |
|--|---|--|
| \$2,184 \$2,003 \$112 836.9 | \$2,647 \$2,372 \$134 | 21.2% 18.4% |
| \$2,003 \$112 836.9 | \$2,372 \$134 | 18.4% |
| \$112 836.9 | \$134 | |
| 836.9 | • | 18.9% |
| | 757.1 | |
| \$4.66 | | -9.5% |
| ÷ | \$5.51 | 18.1% |
| 468.4 | 480.5 | 2.6% |
| \$121 | \$143 | 17.6% |
| \$114 | \$133 | 16.9% |
| \$7 | \$8 | 16.1% |
| 44.8 | 47.1 | 5.1% |
| \$3.14 | \$3.70 | 17.8% |
| 38.7 | 38.6 | -0.2% |
| \$1,017 | \$1,322 | 30.0% |
| \$913 | \$1,198 | 31.3% |
| \$97 | \$118 | 20.9% |
| 833.8 | 751.9 | -9.8% |
| \$2.41 | \$3.06 | 26.7% |
| 421.3 | 432.4 | 2.6% |
| \$1,046 | \$1,182 | 12.9% |
| \$976 | \$1,041 | 6.6% |
| \$8 | \$8 | -3.3% |
| 42.1 | 43.6 | 3.5% |
| \$124.75 | \$125.70 | 0.8% |
| 8.4 | 9.4 | 12.1% |
| | 468.4 \$121 \$114 \$7 44.8 \$3.14 38.7 \$1,017 \$913 \$97 833.8 \$2.41 421.3 \$1,046 \$976 \$8 42.1 \$124.75 | 468.4480.5\$121\$143\$114\$133\$114\$133\$7\$844.847.1\$3.14\$3.7038.738.6\$1,017\$1,322\$913\$1,198\$97\$118\$33.8751.9\$2.41\$3.06421.3432.4\$1,046\$1,182\$976\$1,041\$8\$842.143.6\$124.75\$125.70 |




*Specialty drugs on this slide includes drugs covered under the prescription drug benefit and excludes drugs covered under the medical plans.

© 2024 Merative

Prescription Drug Detail: Non-Specialty Drugs

Annual Trend

| | Allowed Amount PMPY | | Net Pay PMPY A | | Allowed | Allowed Amt per Days Supply | | Days Supply PMPY | | | Generic Efficiency | | | | |
|----------------------------|---------------------|------------|----------------|------------|------------|-----------------------------|------------|------------------|----------|------------|--------------------|----------|------------|------------|----------|
| | Nov 2022 | Nov 2023 | | Nov 2022 | Nov 2023 | | Nov 2022 | Nov 2023 | | Nov 2022 | Nov 2023 | | Nov 2022 | Nov 2023 | |
| Therapeutic Class | - Oct 2023 - | - Oct 2024 | % Change | - Oct 2023 | - Oct 2024 | % Change | - Oct 2023 | - Oct 2024 | % Change | - Oct 2023 | - Oct 2024 | % Change | - Oct 2023 | - Oct 2024 | % Change |
| Hormones & Synthetic Subst | \$543 | \$810 | 49.0% | \$515 | \$774 | 50.4% | \$7 | \$9 | 37.1% | 83 | \$90 | 8.7% | 93.2% | 94.9% | 1.8% |
| Central Nervous System | \$228 | \$245 | 7.3% | \$200 | \$214 | 7.2% | \$2 | \$2 | 4.4% | 116 | \$119 | 2.8% | 98.6% | 96.8% | -1.8% |
| Cardiovascular Agents | \$51 | \$61 | 20.8% | \$38 | \$45 | 18.1% | \$0 | \$1 | 19.8% | 120 | \$121 | 0.8% | 100.0% | 99.9% | 0.0% |
| Blood Form/Coagul Agents | \$49 | \$54 | 10.5% | \$46 | \$51 | 10.2% | \$9 | \$9 | 5.8% | 6 | \$6 | 4.4% | 99.8% | 99.9% | 0.1% |
| Gastrointestinal Drugs | \$38 | \$42 | 11.7% | \$34 | \$36 | 8.4% | \$2 | \$2 | 9.6% | 25 | \$26 | 1.9% | 99.9% | 99.9% | 0.0% |
| Anti-Infective Agents | \$24 | \$41 | 68.4% | \$18 | \$33 | 83.5% | \$2 | \$3 | 62.4% | 12 | \$13 | 3.7% | 99.9% | 100.0% | 0.0% |
| Serums, Toxoids, Vaccines | \$31 | \$38 | 23.0% | \$31 | \$38 | 23.1% | \$83 | \$111 | 35.1% | 0 | \$0 | -8.9% | 100.0% | 100.0% | 0.0% |
| Autonomic Drugs | \$32 | \$29 | -8.2% | \$28 | \$25 | -11.1% | \$3 | \$2 | -9.4% | 12 | \$12 | 1.3% | 99.9% | 100.0% | 0.1% |
| Eye, Ear, Nose Throat | \$27 | \$27 | 0.6% | \$22 | \$22 | 0.1% | \$2 | \$3 | 22.0% | 11 | \$9 | -17.5% | 97.9% | 97.6% | -0.4% |
| Diagnostic Agents | \$30 | \$25 | -16.4% | \$25 | \$20 | -22.4% | \$3 | \$4 | 3.4% | 9 | \$7 | -19.1% | 0.0% | 0.0% | 0.0% |
| All Other Values | \$84 | \$92 | 8.8% | \$70 | \$72 | 3.9% | \$1 | \$1 | 5.5% | 65 | \$67 | 3.1% | 99.3% | 99.3% | 0.0% |
| Total | \$1,138 | \$1,465 | 28.7% | \$1,026 | \$1,331 | 29.7% | \$2 | \$3 | 25.7% | 460 | \$471 | 2.4% | 98.6% | 98.2% | -0.4% |



Specialty Drug Detail¹

| | Allowed Amount | | | Patients | | | Allowed Amount per Patient | | | |
|------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|----------------------------|------------------------|----------|--|
| | Nov 2022 - Oct 2023 | Nov 2023 - Oct 2024 | % Change | Nov 2022 - Oct 2023 | Nov 2023 - Oct 2024 | % Change | Nov 2022 - Oct 2023 | Nov 2023 - Oct 2024 | % Change | |
| Medical Specialty | \$63,093,043 | \$74,561,399 | 18.2% | 3,517 | 3,916 | 11.3% | \$17,939 | \$19,040 | 6.1% | |
| Prescription Specialty | \$105,055,297 | \$121,488,283 | 15.6% | 4,669 | 4,969 | 6.4% | \$22,501 | \$24,449 | 8.7% | |

| То | p 10 Specialty Drugs Through Medical Plans | Allowed Amount | Patients | Allowed/Patient |
|----------------|--|----------------|----------|-----------------|
| J9271 | Inject pembrolizumab 1 mg | \$7,099,418 | 59 | \$120,329 |
| J2350 | Inject, ocrelizumab, 1 mg | \$4,004,617 | 55 | \$72,811 |
| J2506 | Inject, pegfilgrastim, excl biosimilar, 0.5 mg | \$3,370,719 | 63 | \$53,503 |
| J9299 | Inject nivolumab 1 mg | \$2,549,633 | 17 | \$149,978 |
| J9144 | Inj, daratumumab, 10 mg and hyaluronidase-fihj | \$2,177,263 | 16 | \$136,079 |
| J3380 | Inject, vedolizumab, intravenous, 1 mg | \$2,022,796 | 55 | \$36,778 |
| J3241 | Inject, teprotumumab-trbw, 10 mg | \$1,967,079 | 3 | \$655,693 |
| 96413 | CHEMOTX ADMN IV NFS TQ | \$1,954,753 | 559 | \$3,497 |
| J2323 | Injection natalizumab, 1 mg | \$1,739,956 | 15 | \$115,997 |
| J0585 | Injection onabotulinumtoxinA, 1 unit | \$1,425,499 | 338 | \$4,217 |
| Total Top 10 | | \$26,886,234 | 842 | \$31,931 |
| Percent of Ove | rall Total (Medical Specialty) | 36.1% | 21.5% | |

¹Specialty drugs are defined in a Merative service category group and include drugs paid under the prescription benefit and the medical benefit. Although there is no consensus definition, the continuum of drugs included may have the following characteristics: relatively costly (at least \$670 per month for a 30-day supply, according to CMS); often injected or infused; involve a significant degree of patient education, monitoring and management; require special preparation, handling or monitoring; and may be biologically created vs. a chemical compound.

Specialty Drug Detail


| Top 15 Through the Prescription Plan | Allowed Amount | Patients |
|---|----------------|----------|
| STELARA | \$9,026,801 | 82 |
| TREMFYA | \$6,350,774 | 114 |
| DUPIXENT PEN | \$6,286,233 | 234 |
| HUMIRA | \$5,672,864 | 184 |
| SKYRIZI | \$5,090,242 | 91 |
| ENBREL | \$3,086,031 | 54 |
| COSENTYX | \$2,789,259 | 55 |
| TALTZ | \$2,683,673 | 45 |
| DUPIXENT PFS | \$2,337,313 | 89 |
| RINVOQ | \$2,322,969 | 56 |
| TRIKAFTA | \$2,307,998 | 8 |
| BIKTARVY | \$2,141,870 | 70 |
| OTEZLA | \$2,112,217 | 68 |
| HYRIMOZ | \$1,695,253 | 182 |
| SPRYCEL | \$1,571,021 | 13 |
| Total Top 15 | \$55,474,519 | 1,345 |
| Percent of Overall Total (Rx Specialty) | 45.7% | 27.1% |

Top 15 Through the Prescription Plan

Mental Health and Substance Abuse Detail

| | M | ental Health | | Substance Abuse | | | |
|-----------------------------|------------|--------------|----------|-----------------|------------|----------|--|
| | Nov 2022 – | Nov 2023 – | | Nov 2022 – | Nov 2023 – | | |
| | Oct 2023 | Oct 2024 | % Change | Oct 2023 | Oct 2024 | % Change | |
| Overall | | | | | | | |
| Patients per 1000 Inpatient | 4.3 | 4.0 | -7.2% | 1.6 | 1.5 | -3.8% | |
| Pats per 1000 Outpatient | 213.8 | 217.3 | 1.6% | 9.1 | 9.8 | 7.9% | |
| Inpatient | | | | | | | |
| Allow Amt PMPY Adm Acute | \$61 | \$60 | -0.6% | \$26 | \$31 | 20.1% | |
| Net Pay PMPY Adm Acute | \$58 | \$59 | 0.4% | \$24 | \$29 | 20.2% | |
| Allow Amt Per Adm Acute | \$14,960 | \$16,347 | 9.3% | \$12,422 | \$13,151 | 5.9% | |
| Days LOS Admit Acute | 10.6 | 10.4 | -1.4% | 9.9 | 9.3 | -6.6% | |
| Admits Per 1000 Acute | 4.1 | 3.7 | -9.1% | 2.1 | 2.4 | 13.5% | |
| Outpatient | | | | | | | |
| Allow Amt PMPY OP Med | \$277 | \$317 | 14.5% | \$29 | \$34 | 17.3% | |
| Net Pay PMPY OP Med | \$252 | \$284 | 12.5% | \$27 | \$31 | 16.5% | |
| Allow Amt Per Svc OP Med | \$106 | \$115 | 8.1% | \$136 | \$138 | 1.6% | |
| Svcs Per 1000 OP Med | 2610.2 | 2764.3 | 5.9% | 212.9 | 246.0 | 15.5% | |

Preventive Visits and Screening Overview




Clinical Overview

| Annual Trend: Conditions of Interest | Allowed Amount PMPY (Medical) | | Patie | ents per 1000 | | Allowed Amount per Patient (Medical) | | | |
|--------------------------------------|-------------------------------|------------|--------|---------------|------------|--------------------------------------|-------------|-------------|--------|
| | Nov 2022 – | Nov 2023 – | | Nov 2022 – | Nov 2023 – | | Nov 2022 – | Nov 2023 – | |
| | Oct 2023 | Oct 2024 | Change | Oct 2023 | Oct 2024 | Change | Oct 2023 | Oct 2024 | Change |
| Asthma | \$28.77 | \$29.49 | 2.5% | 37.5 | 39.0 | 4.0% | \$695.30 | \$682.56 | -1.8% |
| Cancer - Breast | \$123.42 | \$159.90 | 29.6% | 7.1 | 7.3 | 2.3% | \$15,664.95 | \$19,756.55 | 26.1% |
| Cancer - Colon | \$34.53 | \$23.50 | -31.9% | 1.7 | 1.5 | -10.5% | \$18,539.73 | \$14,045.19 | -24.2% |
| Cancer - Lung | \$35.91 | \$32.09 | -10.6% | 1.2 | 1.1 | -4.2% | \$27,311.27 | \$25,374.31 | -7.1% |
| Cancer - Skin | \$30.02 | \$34.63 | 15.4% | 29.5 | 28.5 | -3.3% | \$923.07 | \$1,096.38 | 18.8% |
| Cerebrovascular Disease | \$85.48 | \$96.02 | 12.3% | 11.9 | 12.1 | 0.9% | \$6,481.71 | \$7,188.90 | 10.9% |
| Chronic Obstruc Pulm Dis(COPD) | \$11.63 | \$11.48 | -1.3% | 5.4 | 5.1 | -5.2% | \$1,948.86 | \$2,020.92 | 3.7% |
| Congestive Heart Failure | \$22.70 | \$16.18 | -28.7% | 3.3 | 3.4 | 3.5% | \$6,312.37 | \$4,331.20 | -31.4% |
| Coronary Artery Disease | \$106.08 | \$106.44 | 0.3% | 14.7 | 15.2 | 3.1% | \$6,521.87 | \$6,321.23 | -3.1% |
| Diabetes | \$105.65 | \$109.84 | 4.0% | 97.7 | 103.8 | 6.2% | \$979.95 | \$955.29 | -2.5% |
| Hypertension, Essential | \$77.98 | \$87.09 | 11.7% | 118.8 | 117.1 | -1.5% | \$594.53 | \$671.34 | 12.9% |
| Mental Hlth - Depression | \$83.83 | \$90.46 | 7.9% | 59.5 | 58.4 | -1.8% | \$1,277.31 | \$1,397.68 | 9.4% |
| Osteoarthritis | \$201.91 | \$175.25 | -13.2% | 62.2 | 62.5 | 0.5% | \$2,938.80 | \$2,529.25 | -13.9% |
| Renal Function Failure | \$112.10 | \$100.16 | -10.7% | 11.2 | 11.8 | 5.3% | \$9,047.46 | \$7,649.77 | -15.4% |
| Spinal/Back Disord, Low Back | \$173.95 | \$206.74 | 18.8% | 99.4 | 97.8 | -1.6% | \$1,585.42 | \$1,908.15 | 20.4% |
| Pneumonia | \$26.00 | \$41.00 | 57.7% | 7.7 | 11.1 | 43.7% | \$3,060.52 | \$3,345.27 | 9.3% |
| Pregnancy | \$303.56 | \$306.18 | 0.9% | 24.7 | 23.7 | -4.1% | \$11,151.72 | \$11,679.09 | 4.7% |

Risk Profile¹ (Based on FY24 Claims Experience)

| | Member Age Avg | Allowed Amount | Allow Amt PMPY | Patients |
|------------|----------------|----------------|----------------|----------|
| Healthy | 24.9 | \$24,128,952 | \$791 | 27,448 |
| Stable | 29.6 | \$71,969,163 | \$2,946 | 25,922 |
| At Risk | 39.8 | \$182,992,838 | \$7,141 | 27,385 |
| Struggling | 46.0 | \$363,731,209 | \$20,410 | 19,243 |
| In Crisis | 50.5 | \$339,501,120 | \$97,537 | 3,947 |



© 2024 Merative

¹Definitions for each of the risk category are included on the next slide.

Risk Categories

- Healthy represents nearly 50% of the privately insured under-65 U.S. population, who account for less than 5% of total healthcare cost. Most patients in this category are infrequent or non-utilizers of the healthcare system, most often being treated for occasional low severity acute conditions.
- **Stable** represents nearly 25% of the privately insured under-65 U.S. population, who account for 10-15% of total healthcare cost. Most patients in this category are somewhat active utilizers of the healthcare system, most often being treated for low-severity acute conditions.
- At Risk represents between 15 and 20% of the privately insured under-65 U.S. population, who account for 20-25% of total healthcare cost. Most patients in this category are active utilizers of the healthcare system, most often being treated for multiple medium-severity acute conditions and/or low-severity chronic conditions.
- **Struggling** represents between 5 and 10% of the privately insured under-65 U.S. population, who account for 25-30% of total healthcare cost. Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple high-severity acute conditions and/or medium-severity chronic conditions.
- In-Crisis represents the top 2% of the privately insured under-65 U.S. population, who account for approximately 30% of total healthcare cost. Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple severe acute and/or chronic conditions.

Appendix: Outpatient Radiology Detail PET Scans, Nuclear Medicine & Therapeutic Radiology

| | Freestanding Facilities | | | Hospitals (Outpatient) | | | | |
|-----------------------|-------------------------|-------------|--------------------------------|------------------------|-------------|--------------------------------|--|--|
| | Utilization Trend | Price Trend | Total Allowed Amount Change | Utilization Trend | Price Trend | Total Allowed Amount Change | | |
| Pet Scans | 72.3% | 6.9% | \$150,809 | -2.5% | 15.9% | \$282,186 | | |
| Nuclear Medicine | -12.8% | -10.1% | -\$101,347 | -1.8% | 65.2% | \$1,192,598 | | |
| Therapeutic Radiology | -35.8% | -18.6% | -\$300,375 | 21.0% | 8.2% | \$3,544,832 | | |
| Total | -14.8% | -7.0% | -\$250,913 | 15.8% | 14.6% | \$5,019,616 | | |

The overall trend increase in allowed amount PMPY for outpatient radiology services in the current reporting period (November 2023 – October 2024) was primarily driven for services performed at hospital locations. The primary procedures performed at hospitals in the therapeutic radiology service group that contributed to this increase were radiation therapy procedures. Both utilization (an increase of 21%) and price (an increase of 8.2%) were factors. The price of both nuclear medicine services and PET Scans at hospitals were also factors (increases of 65.2% and 15.9%, respectively. Procedures driving the increase in price for nuclear medicine include myocardial perfusion SPECT studies and imaging studies related to cancer. Though there was a 72% increase in utilization of PET scans at freestanding facilities (primarily services at out-of-state facilities, the overall utilization at non-hospital locations remains low (3.3 services per 1,000 – data not displayed).